These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33515202)

  • 1. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients.
    Selby PR; Shakib S; Peake SL; Warner MS; Yeung D; Hahn U; Roberts JA
    Clin Pharmacokinet; 2021 Jun; 60(6):727-739. PubMed ID: 33515202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
    Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
    Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
    Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
    Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
    Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
    Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients.
    Franck B; Autmizguine J; Åsberg A; Théorêt Y; Marquet P; Ovetchkine P; Woillard JB
    Clin Pharmacokinet; 2021 Nov; 60(11):1449-1462. PubMed ID: 34050910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
    Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
    Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach.
    Lalagkas PN; Iliou J; Rigo R; Miarons M; Fernández-Alarcon B; Bestard O; Cruzado JM; Melilli E; Torras J; Grinyó JM; Lloberas N; Colom H
    Clin Pharmacokinet; 2023 Jun; 62(6):861-880. PubMed ID: 37140726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valganciclovir-Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship.
    Galar A; Valerio M; Catalán P; García-González X; Burillo A; Fernández-Cruz A; Zataráin E; Sousa-Casasnovas I; Anaya F; Rodríguez-Ferrero ML; Muñoz P; Bouza E
    Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33467490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
    Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N
    Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
    Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD
    Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.
    Li QY; van den Anker J; Wu YE; Hao GX; Zhao W
    Expert Rev Clin Pharmacol; 2023; 16(8):727-739. PubMed ID: 36794592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
    Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
    Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
    J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.
    Lefeuvre S; Chevalier P; Charpentier C; Zekkour R; Havard L; Benammar M; Amrein C; Boussaud V; Lillo-Le Louët A; Guillemain R; Billaud EM
    Transpl Infect Dis; 2010 Jun; 12(3):213-9. PubMed ID: 20102551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K; Greser A; Wanner C
    Clin Transplant; 2007; 21(1):80-5. PubMed ID: 17302595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland.
    Jedlińska-Pijanowska D; Czech-Kowalska J; Kłodzińska M; Pietrzyk A; Michalska E; Gradowska K; Dobrzańska A; Kasztelewicz B; Gruszfeld D
    Adv Clin Exp Med; 2020 Oct; 29(10):1161-1167. PubMed ID: 33053275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.